$3.54
+0.03(0.71%)
Mkt Cap $1.1B
$1.93
$6.17
52-Week Range
At A Glance
1
AbCellera Biologics Inc.
2
Most recently: Results of Operations and Financial Condition On February 24, 2026, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial an (2026-02-24).
$1.1B
Market Cap
$76M
Revenue
-$149M
Net Income
Employees596
Fundamentals
How The Business Makes Money
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001703057
ISINCA00288U1066
CUSIP00288U106
Phone604 559 9005
Address2215 Yukon Street, Vancouver, BC, V5Y 0A1, CA
SEC EDGAR